Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made notable portfolio move on Monday, April 27, 2026, as shown in ARK’s daily fund disclosures. The firm continued to reduce its position in the aerospace firm, Rocket Lab (RKLB), while doubling down on gene-editing growth by taking advantage of a sharp pullback in Intellia Therapeutics (NTLA).
Claim 55% Off TipRanks
New trading tool for ARKK bulls/bearsWood Trims Rocket Lab Stake Following Recent Gains
The most significant move of the day was the sale of 50,312 shares of Rocket Lab through the ARK Autonomous Technology & Robotics ETF (ARKQ), totaling approximately $4.01 million. This follow-up move comes after ARK sold over 113,000 shares last Friday, signaling a sustained reduction in Wood’s conviction for the space stock.
Interestingly, Wood is selling even as the stock remains resilient, with RKLB closing Monday’s session up 3.28% at $82.29. Despite the positive price action, the firm appears to be locking in profits ahead of Rocket Lab’s Q1 2026 earnings report, scheduled for May 7, 2026.
For the upcoming report, Wall Street analysts expect revenues to reach $189.65 million, up 55% year-over-year. At the same time, they project a loss per share at $0.07, lower than the loss of $0.12 per share in the year-ago quarter.
What Is the Prediction for RKLB Stock?
Ahead of the results, Stifel analyst Erik Rasmussen raised his price target on RKLB to $105 from $90 and kept a Buy rating on the stock. He said the firm remains confident in Rocket Lab after meeting its management at the 41st annual Space Symposium. The analyst pointed to the company’s steady revenue growth, a strong and growing backlog, and the expected launch of its Neutron rocket later this year as key positives.
According to TipRanks, RKLB stock has received a Moderate Buy consensus rating, with nine Buys and four Holds assigned in the last three months. The average price target for Rocket Lab is $89.0, suggesting an upside of 8.15% from the current level.
Wood ‘Buys the Dip’ in Intellia Ahead of Earnings
While Wood scaled back on aerospace, she moved aggressively into the biotechnology sector. ARK acquired 263,848 shares of Intellia across its ARK Innovation ETF (ARKK) and ARK Genomic Revolution ETF (ARKG) funds. The investment, valued at roughly $3.6 million, represents a clear “buy the dip” strategy.
Shares of NTLA fell 4.4% on Monday, closing at $13.03. The sell-off occurred despite the company reporting positive Phase 3 trial data for its hereditary angioedema (HAE) therapy earlier in the day. Wood likely views this negative market reaction as a buying opportunity, especially with the company’s Q1 earnings report due this Thursday, April 30, 2026.
For the upcoming report, Wall Street analysts expect revenues of $13.57 million, down from $16.63 million a year ago. Meanwhile, they expect the company to post a loss per share of $0.91, compared to a loss of $1.10 per share in the same quarter last year.
By bolstering her holdings now, Wood is positioning ARK for a potential rebound if the company provides positive commentary on its Biologics License Application (BLA) timeline during the conference call.
Is NTLA Stock a Buy or Hold Right Now?
According to TipRanks, NTLA stock has received a Moderate Buy consensus rating, with nine Buys, seven Holds, and one Sell assigned in the last three months. The average price target for Intellia is $22.64, suggesting an upside of 73.64% from the current level.
